Abl inhibitor BMS354825 binding mode in Abelson kinase revealed by molecular docking studies |
|
Focal adhesion kinase (FAK) binds RET kinase via its FERM domain, priming a direct and reciprocal RET-FAK transactivation mechanism. |
|
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia |
|
FusionAnalyser: a new graphical, event-driven tool for fusion rearrangements discovery |
|
Gene expression signature of non-involved lung tissue associated with survival in lung adenocarcinoma patients. |
|
hnRNP A1 nucleocytoplasmic shuttling activity is required for normal myelopoiesis and BCR/ABL leukemogenesis |
|
How "precise" is precision medicine in hematology? |
|
Identification of genetic polymorphisms modulating nausea and vomiting in two series of opioid-treated cancer patients |
|
Identification of novel point mutations in splicing sites integrating whole-exome and RNA-seq data in myeloproliferative diseases. |
|
Identification of novel posttranscriptional targets of the BCR/ABL oncoprotein by ribonomics: requirement of E2F3 for BCR/ABL leukemogenesis |
|
Imatinib--A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015. |
|
Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis |
|
Imatinib does not substantially modify the glycemic profile in patients with chronic myeloid leukaemia |
|
Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. |
|
Imatinib-loaded polyelectrolyte microcapsules for sustained targeting of BCR-ABL+ leukemia stem cells. |
|
Immunogenicity of fusion proteins. An example of tumor-specific/transformation-related antigens. |
|
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells |
|
In vitro and in vivo identification of ABCB1 as an efflux transporter of bosutinib |
|
In Vitro Transcriptional and Translational Block of the bcl-2 Gene Operated by Peptide Nucleic Acid |
|
In vivo T-cell immune response against anaplastic lymphoma kinase in patients with anaplastic large cell lymphomas |
|
Increased sFLT1/PlGF ratio in COVID-19: a novel link to Angiotensin II-mediated endothelial dysfunction |
|
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. |
|
Inhibitors of the RET tyrosine kinase based on a 2-(alkylsulfanyl)-4-(3-thienyl)nicotinonitrile scaffold |
|
Killer immunoglobulin-like receptors can predict TKI treatment-free remission in chronic myeloid leukemia patients |
|
Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia |
|
Locking Src/Abl Tyrosine Kinase Activities Regulate Cell Differentiation and Invasion of Human Cervical Cancer Cells Expressing E6/E7 Oncoproteins of High-Risk HPV |
|
Long-term and low-dose of busulfan is a safe and effective second-line treatment in elderly patients with essential thrombocythemia resistant or intolerant to hydroxyurea. |
|
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib |
|
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors |
|
Lysis by interleukin 2-stimulated tumor-infiltrating lymphocytes of autologous and allogeneic tumor target cells |
|
Management of adverse events associated with bosutinib treatment of chronic-phase chronic myeloid leukemia: expert panel review |
|
A mechanistic design principle for protein tyrosine kinase sensors: application to a validated cancer target. |
|
Mitochondrial Hyperactivation and Enhanced ROS Production are Involved in Toxicity Induced by Oncogenic Kinases Over-Signaling |
|
Molecular cytogenetics of the acute promyelocytic leukemia-derived cell line NB4 and of four all-trans retinoic acid-resistant subclones |
|
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. |
|
Morgana acts as an oncosuppressor in chronic myeloid leukemia. |
|
Mutation-independent anaplastic lymphoma kinase overexpression in poor prognosis neuroblastoma patients |
|
A needle in a haystack: Identifying biomarkers to personalize systemic therapy in patients with hepatocellular carcinoma |
|
The Novel PIM1 Inhibitor NMS-P645 Reverses PIM1-Dependent Effects on TMPRSS2/ERG Positive Prostate Cancer Cells And Shows Anti-Proliferative Activity in Combination with PI3K Inhibition |
|
NPM/ALK binds and phosphorylates the RNA/DNA-binding protein PSF in anaplastic large-cell lymphoma |
|
NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922 |
|
Of nicks and time |
|
Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy |
|
Panniculitis during Dasatinib Therapy for Imatinib-Resistant Chronic Myelogenous Leukemia |
|
Part I: Milestones in personalised medicine--imatinib |
|
Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate |
|
Personal history and quality of life in chronic myeloid leukemia patients: a cross-sectional study using narrative medicine and quantitative analysis |
|
Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype |
|
PNAs as novel cancer therapeutics |
|
Ponatinib is a potent inhibitor of wild-type and drug-resistant gatekeeper mutant RET kinase |
|
Procoagulant and fibrinolytic activity of human ovarian carcinoma cells in culture. |
|
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells |
|
A rapid method for the purification of wild-type and V804M mutant ret catalytic domain: A tool to study thyroid cancer |
|
Reply to P. Laneuville et al |
|
RET kinase inhibitors: a review of recent patents (2012-2015). |
|
Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth |
|
RNA-seq is a valuable complement of conventional diagnostic tools in newly diagnosed AML patients |
|
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study. |
|
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia |
|
Selective cytotoxicity of betulinic acid on tumor cell lines, but not on normal cells |
|
Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia |
|
Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease |
|
SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations |
|
Simultaneous development of Philadelphia chromosome-positive and -negative leukemias in the same patient |
|
SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling |
|
Somatic mutations identified at diagnosis by exome sequencing can predict response to imatinib in chronic phase chronic myeloid leukemia (CML) patients |
|
Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. |
|
Sphingosine kinase 1 overexpression is regulated by signaling through PI3K, AKT2, and mTOR in imatinib-resistant chronic myeloid leukemia cells. |
|
STAT3 and TP53 mutations associate with poor prognosis in anaplastic large cell lymphoma |
|
Structural Insights into the ATP Binding Pocket of the Anaplastic Lymphoma Kinase by Site-Directed Mutagenesis, Inhibitor Binding Analysis, and Homology Modeling |
|
Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma |
|
Synergistic activity of the Src/Abl inhibitor bosutinib in combination with imatinib |
|
Synergistic effects of combined Wnt/KRAS inhibition in colorectal cancer cells |
|
Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors |
|
Synthesis, structure-activity relationship and crystallographic studies of 3-substituted indolin-2-one RET inhibitors |
|
Systemic administration of autologous, alloactivated helper-enriched lymphocytes to patients with metastatic melanoma of the lung. A phase I study. |
|
Too many agencies spoil Euro research |
|
Treatment Patterns in Patients with Chronic-Phase Chronic Myeloid Leukaemia in Routine Clinical Practice: the SIMPLICITY Italian Population. |
|
Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity |
|
Validation of PDGFRbeta and c-Src tyrosine kinases as tumor/vessel targets in patients with multiple myeloma: preclinical efficacy of the novel, orally available inhibitor dasatinib |
|
Valproic acid enhances bosutinib cytotoxicity in colon cancer cells |
|